Can my GP now prescribe ADHD medication without a specialist referral?

Not yet — the PBAC recommendation still needs to complete the legislative process before it becomes a live PBS listing. Once it does, GPs will be able to initiate certain non-stimulant ADHD medications (atomoxetine and guanfacine) for patients who have tried stimulants without adequate response. Stimulants (like dexamphetamine and methylphenidate) remain under separate recommendations that are still in progress.

Why does this matter for women with ADHD specifically?

ADHD in women is significantly underdiagnosed, partly because the diagnostic frameworks were developed in male populations. Adult women presenting with ADHD symptoms often face both the standard specialist waitlist and the additional burden of having their symptoms attributed to anxiety or depression. GP-initiated treatment reduces one layer of that barrier.

GPs cleared to start ADHD medications: what the PBAC change means

If you have been waiting — or you know someone who has been waiting — for an ADHD assessment, there is a policy shift announced this week that is genuinely worth tracking.

The Pharmaceutical Benefits Advisory Committee (PBAC) recommended at its September 2026 meeting that PBS-subsidised access to two non-stimulant ADHD medicines, atomoxetine and guanfacine, be extended — and more significantly, that GPs be able to initiate treatment rather than requiring a specialist to start the prescription.

This is a partial answer to something that has been broken in Australian healthcare for a long time.

What the system currently looks like

To access PBS-subsidised ADHD medication in Australia right now, you need a specialist — a psychiatrist or paediatrician — to initiate the prescription. GPs can continue prescribing once the specialist starts, but they cannot begin.

The practical problem is that specialist waitlists for adult ADHD assessment in Australian cities routinely run to 12–18 months. Private assessments cost $1,000–$2,500 out of pocket for many patients. In regional and rural areas, specialist access is even thinner.

The result: adults who strongly suspect they have ADHD — often people in their 30s and 40s who were not diagnosed in childhood, frequently women whose symptoms presented differently than the hyperactive-boy archetype the diagnostic criteria were written around — are stuck waiting. Meanwhile, untreated ADHD affects work, relationships, sleep, and mental health in ways that compound every month they wait.

A 2023 Senate inquiry made it explicit: the current access structure is causing harm. The PBAC’s September 2026 recommendations are a direct, if partial, response to what that inquiry found.

What the recommendation actually changes

The specific changes recommended cover two non-stimulant ADHD medicines:

Atomoxetine (a noradrenaline reuptake inhibitor, often used when stimulants cause intolerable side effects or where there’s comorbid anxiety)
Guanfacine (an alpha-2 agonist, used where stimulants aren’t tolerated or as an adjunct)

Both would remain second-line options — they’re for patients who trialled stimulants but didn’t respond adequately. The stimulant medications (dexamphetamine, methylphenidate) are under a separate, still-in-progress PBAC recommendation tranche. So this is an expansion, but it is not the whole picture.

The headline change is GP initiation. Under the proposed new listing, a GP could start a patient on these non-stimulant medicines without needing a specialist referral first. That is a meaningful structural shift. It won’t eliminate the diagnostic bottleneck — GPs initiating medication still need to be confident in the diagnosis — but it removes one layer of the access problem for patients who are already diagnosed and waiting.

Associate Professor John Kramer, RACGP Specific Interests ADHD Chair, called the recommendation “long overdue” in comments to newsGP. He noted that GPs already possess the skills to manage ADHD and that expanded prescribing access would improve both cost and availability for patients.

Both-and: what this does and doesn’t fix

Let’s be clear about what is genuinely good here, and what is still incomplete.

The genuinely good part: the direction is right. GP-initiated management of a common neurodevelopmental condition — one that presents in clinically meaningful ways in adult life and responds to treatment — is an appropriate scope expansion. GPs managing diabetes, depression, hypertension, and hypothyroidism don’t require a specialist to initiate treatment. ADHD is not categorically different.

The incomplete part: atomoxetine and guanfacine are second-line for a reason. They work well for some patients, but the primary clinical experience of adult ADHD treatment begins with stimulants. The PBAC recommendation for stimulants is a “further tranche” that has not yet landed. Until it does, GP initiation helps a subset — the patients who specifically didn’t tolerate stimulants, or for whom non-stimulants are indicated — but not the majority of adults newly starting treatment.

There is also the question of how GPs will be supported in ADHD diagnosis. Prescribing access is one barrier. Clinical confidence in diagnosing adult ADHD — particularly in women, where the presentation is often primarily inattentive, masked, or wrapped in comorbid anxiety and depression — is another. Prescribing rights without diagnostic support pathways only close part of the gap.

And the recommendation is not yet a live PBS listing. Post-PBAC decisions follow a legislative process that typically takes several months.

2 cents: what this means for your terrain this week

If you are an adult managing ADHD — or strongly suspecting you might be and waiting in the access queue — this week’s news does not change what is available to you today. But it clarifies direction.

A few things worth doing now:

If you’re diagnosed but waiting for a specialist to initiate treatment: Ask your GP whether they are comfortable managing ADHD medication. Some GPs are already skilled at this and willing to initiate in a shared-care model. The formal PBS change has not yet happened — but clinical practice sometimes moves ahead of policy, particularly when patients ask.

If you’re undiagnosed and self-suspecting: A GP appointment to discuss your symptoms and request a referral is the right starting point. The referral pipeline is still long. Starting it now, rather than waiting for policy to change, is the faster path.

If your ADHD symptoms have been attributed to anxiety, depression, or “just stress”: That is a common diagnostic pattern, particularly for women. ADHD and anxiety frequently co-exist — the anxiety is often driven by untreated ADHD, not independent of it. Naming both explicitly, and asking for a specialist referral specifically for ADHD assessment, is appropriate.

The system is starting to catch up with the actual clinical burden of adult ADHD. Slowly. But the trajectory matters — and knowing it helps you advocate for yourself more effectively in the appointments you’re having right now.

Verdict: yes — this is worth knowing about.